Skip to main content

Table 2 Comparison of laboratory findings, circulating galectin-3 level and Lp-PLA2 gene expression between day 0 and day 90 after combined clopidogrel and cilostazol treatment among 55 study patients

From: Levels and values of lipoprotein-associated phospholipase A2, galectin-3, RhoA/ROCK, and endothelial progenitor cells in critical limb ischemia: pharmaco-therapeutic role of cilostazol and clopidogrel combination therapy

Variable Day 0 Day 90 p-value
Red blood cell count (×106) 4.0 ± 0.8 3.8 ± 0.7 0.682
White blood cell count (×103) 8.2 ± 3.2 8.0 ± 2.2 0.574
Platelet count (×103) 250 ± 78 236 ± 115 0.483
Hemoglobin 11.5 ± 2.1 11.1 ± 2.1 0.811
Total cholesterol level 181 ± 52 152 ± 22 < 0.001
Low-density lipoprotein 106 ± 43 79 ± 24 < 0.001
High-density lipoprotein 55 ± 14 58 ± 14 0.001
Creatinine level (mg/dL) 3.23 ± 3.31 3.35 ± 3.46 0.731
Ac sugar 158 ± 76 148 ± 41 0.103
HbA1c 7.28 ± 1.65 6.80 ± 0.92 0.001
Lp-PLA2 1.46 ± 0.10 1.37 ± 0.09 < 0.001
Galectin-3 (ng/ml) 23.09 ± 4.17 15.53 ± 4.33 < 0.001
CD31+/CD34+ (%) 0.77 ± 0.48 0.80 ± 0.56 0.001
KDR+/CD34+ (%) 0.84 ± 0.55 0.89 ± 0.39 < 0.001
CXCR4+/CD34+ (%) 1.10 ± 0.70 1.11 ± 0.89 0.002
  1. Data are expressed as mean ± SD.
  2. Lp-PLA2 = lipoprotein-associated phospholipase A2.